Sunshine Biopharma, Inc. cash flow to debt ratio of -656.20% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sunshine Biopharma, Inc.'s free cash flow has increased -62.93% from $-14.85M last year to $-5.51M, signaling increasing performance

Sunshine Biopharma, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Sunshine Biopharma, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.03 today, signaling strengthened financials

Sunshine Biopharma, Inc. has a net cash position, so leverage is healthy.

Sunshine Biopharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Sunshine Biopharma, Inc.'s profit margin has decreased (15.58%) in the last year from -14.72% to -17.01%, signaling decreasing performance

Sunshine Biopharma, Inc.'s short-term assets of $26.85M exceed its short-term liabilities of $6.44M

Sunshine Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sunshine Biopharma, Inc.'s return on equity of -25.58%, is lower than 15.00%, indicating bad performance

Sunshine Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sunshine Biopharma, Inc. has insufficient public price history to evaluate earnings stability.

Sunshine Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sunshine Biopharma, Inc. has negative free cash flow, indicating cash burn

Sunshine Biopharma, Inc.'s yearly earnings has decreased 16.39% since last year from $-5.13M to $-5.98M, signaling decreasing performance

Sunshine Biopharma, Inc.'s yearly revenue has increased 4.11% since last year from $34.87M to $36.31M, signaling increasing performance

ROIC -20.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sunshine Biopharma, Inc.'s 3-year revenue CAGR of 102.91% is positive, indicating growing revenue over the past 3 years

Sunshine Biopharma, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Sunshine Biopharma, Inc. has insufficient public price history to evaluate ROE consistency.

Sunshine Biopharma, Inc. has insufficient data to evaluate this check.

Sunshine Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sunshine Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sunshine Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sunshine Biopharma, Inc. has insufficient data to evaluate this check.

Sunshine Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sunshine Biopharma, Inc. has a price-to-book ratio of 0.03x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Sunshine Biopharma, Inc. has a price-to-sales ratio of 0.02x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue